Asia Pacific In Vitro Fertilization Market Size | Companies
The Asia Pacific in vitro fertilization market size was exhibited at USD 8.25 billion in 2023 and is projected to hit around USD 16.85 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 8.86 Billion |
| Market Size by 2033 | USD 16.85 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 7.4% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Procedure, Providers, Instruments, Country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | Japan; China; India; South Korea; Australia |
| Key Companies Profiled | Birla Fertility & IVF; Kitazato Corporation; Amrita Hospital; Morpheus IVF (MLSPL); Babies & Us Fertility IVF & ICSI Center; Southend Fertility Clinic |
Some of the key growth drivers for this market are growing new cases of infertility, increasing availability of in vitro fertilization (IVF) technology treatment, advancements in technology, an increase in the average age of men and women entering marriage, favorable funding offered by governments in the region, and strategic initiatives such as mergers & acquisitions undertaken by key companies in the industry.
Asia Pacific in vitro fertilization market held a 34.5% share of the global market in 2023. Growing new cases of infertility in both men and women are the major issues faced by the population in Asia Pacific. Drastic changes in lifestyle, ever-increasing hours of work, desk-bound nature of work routines, consumption of harmful elements and chemicals through food products, growing occurrence of health issues such as pelvic inflammatory disease, polycystic ovary syndrome, ovarian failure, over/underactive thyroid glands, side effects caused by consumption of drugs and medicines are some of the key root causes leading to infertility.
In recent years, technology has evolved at a rapid pace and the industry has witnessed crucial advancements in technology associated with IVF. Governments in the region have been introducing supportive and encouraging funding for the in vitro fertilization industry for the last few years. Furthermore, the advent of techniques such as Physiological Intra-cytoplasmic Sperm Injection (PICSI), and tactical initiatives such as partnerships, collaborations, mergers & acquisitions (M&A), and expansions implemented by prominent establishments in the industry have been fueling growth for this market in Asia Pacific region.
To enhance the success rate of IVF, companies and governments have been investing resources in research and development associated with assistive technology. Some of the technologies launched through such R&D efforts include Percutaneous Epidydimal Sperm Aspiration & Testicular Sperm Extraction (PESA & TESE), assisted hatching, three-parent IVF, genetic diagnosis, vitrification, mini-IVF, and egg/sperm freezing.
Based on instrument, the culture media segment dominated the market in 2023. Factors driving growth for this segment include a rise in research efforts to improve the culture media and accessibility to necessary funding. The culture media segment entails embryo culture media, cryopreservation media, sperm processing media, and ovum processing media.
The disposable devices segment is anticipated to experience the fastest growth rate during the forecast period. This segment is primarily fueled by aspects such as constant new launches of disposable devices, such as slides, chambers, and needles to adhere to regulatory compliances. Such portfolio developments are expected to generate an increased reception of disposable IVF devices.
Based on procedure, the frozen non-donor segment dominated the market with the largest revenue share in 2023. One of the primary dynamics causing this growth is the cost-effectiveness associated with this procedure. The number of IVF cycles with the aid of frozen non-donor procedures is increasing as compared to other procedures. This technique does not require fertility drug stimulation as well. In addition, the less invasive nature has been acting as a key driver behind the growing demand for this procedure.
The fresh donor segment is anticipated to witness a significant CAGR of 7.3% from 2024 to 2033. Fresh oocytes are fertilized by the fresh donor eggs. A large number of couples are inclined towards the adoption of this procedure as it is expected to provide a better success rate as compared to the frozen eggs procedure.
Based on providers, fertility clinics dominated the market with the largest revenue share in 2023. One of the main aspects fueling growth for this segment is an upsurge in demand for assisted reproductive technology (ART). Furthermore, factors such as the assistance offered by professionals, less or no likelihood of contact with Hospital-Acquired Infections (HAIs), and cost-effectiveness are producing growth for this segment.
Hospitals and other settings segment is likely to experience a CAGR of 7.0% from 2024 to 2033. Asia Pacific region has been going through a vital transition in terms of development and enhancement in healthcare infrastructure. Several specialty hospitals in countries such as India have been providing diligent treatments for infertility, including In-vitro Fertilization (IVF).
Japan In Vitro Fertilization Market Trends
Japan in vitro fertilization market dominated the regional industry and held a revenue share of 34.7% in 2023. This can be attributed to the presence of a defined regulatory framework and the introduction of newer techniques, such as AUGMENT, delayed marriages, lifestyle changes, and a decrease in the birth rate. In addition, the government of Japan has recognized the significance of fertility treatments and it has implemented crucial policies & regulations to support IVF.
India In Vitro Fertilization Market Trends
The in vitro fertilization market in India is likely to experience a CAGR of 8.0% from 2024 to 2033. Factors attributing to this growth are delayed marriages, a rise in the average age of pregnancy, an increase in infertility rates, higher disposable income levels, and awareness about the availability of infertility treatments. With a success rate ranging from 60% to 70%, IVF treatments played a significant role in this growth, attracting a growing number of individuals and couples seeking fertility solutions.
In May 2024, Birla Fertility & IVF, one of the major brands in the India-based IVF industry and wing of the renowned C K Birla Group, acquired ARMC IVF Fertility Centre ensuring its entry into the Southern part of the country. With this acquisition, now Birla Fertility & IVF operates 37 centers across India.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Asia Pacific in vitro fertilization market
Instrument
Procedure
Providers
Country
Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.2. Market Definitions
1.2.1. Procedure Type
1.2.2. Providers
1.2.3. Instrument
1.2.4. Region
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.4.1. Information procurement
1.4.2. Purchased Database
1.4.3. Internal Database
1.4.4. Secondary Sources
1.4.5. Primary Research
1.4.6. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.6.1. Volume Price Analysis
1.6.2. Commodity Flow Analysis
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Research Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.2.1. Procedure Type
2.2.2. End-Use
2.2.3. Instrument
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Market Segmentation
3.3. User Perspective Analysis
3.3.1. Consumer Behavior Analysis
3.3.2. Market Influencer Analysis
3.4. IVF Procedure Pricing Analysis
3.5. Market Dynamics
3.5.1. Market Driver Analysis
3.5.1.1. Rising reprotourism
3.5.1.2. Technological advancements in IVF
3.5.1.3. Favorable government funding
3.5.1.4. Late initiation of family
3.5.1.5. Increasing incidence rate of male and female infertility
3.5.1.6. Mergers and acquisitions (M&A)
3.5.2. Market Restraint Analysis
3.5.2.1. High cost of IVF treatment
3.5.2.2. Lack of regulatory framework and uniform regulations
3.5.2.3. Vulnerability of women depending on cross-border reprotourism
3.6. Industry Analysis Tools
3.6.1. Porter's Five Forces Analysis
3.6.2. PESTLE Analysis
3.6.3. Qualitative Analysis: Impact of COVID-19 on IVF Market
Chapter 4. In Vitro Fertilization Market: Procedure Type Analysis
4.1. In Vitro Fertilization by Procedure Type Market Share Analysis, 2024 & 2033
4.2. Segment Dashboard
4.3. Global In Vitro Fertilization Procedures Market, by Type, 2021 - 2033
4.4. Market Size and Forecasts and Trend Analysis, 2021 - 2033 for the Procedure Type
4.4.1. Fresh Nondonor
4.4.1.1. Fresh nondonor market, 2021 - 2033
4.4.2. Frozen Nondonor
4.4.2.1. Frozen nondonor market, 2021 - 2033
4.4.3. Fresh Donor
4.4.3.1. Fresh donor market, 2021 - 2033
4.4.4. Frozen Donor
4.4.4.1. Frozen donor market, 2021 - 2033
Chapter 5. In Vitro Fertilization Market: Providers Analysis
5.1. In Vitro Fertilization Market: Providers Market Share Analysis, 2024 & 2033
5.2. Segment Dashboard
5.3. Market Size and Forecasts and Trend Analysis, 2021 - 2033 for the following Providers
5.3.1. Fertility Clinics
5.3.1.1. Fertility clinics market, 2021 - 2033
5.3.2. Hospitals and Other Settings
5.3.2.1. Hospitals and other settings market, 2021 - 2033
Chapter 6. In Vitro Fertilization Market: Instrument Analysis
6.1. In Vitro Fertilization (IVF) Market Share Analysis, 2024 & 2033
6.2. Segment Dashboard
6.3. Global IVF Market, by Instrument, 2024 to 2033
6.4. Market Size & Forecasts and Trend Analysis, 2021 to 2033 for the Instrument
6.4.1. Culture Media
6.4.1.1. Culture media market, 2021 - 2033
6.4.1.2. Cryopreservation Media
6.4.1.2.1. Cryopreservation market, 2021 - 2033
6.4.1.3. Embryo Culture Media
6.4.1.3.1. Embryo culture media market, 2021 - 2033
6.4.1.4. Ovum Processing Media
6.4.1.4.1. Ovum processing media market, 2021 - 2033
6.4.1.5. Sperm Processing Media
6.4.1.5.1. Sperm processing media market, 2021 - 2033
6.4.2. Disposable Devices
6.4.2.1. Disposable devices market, 2021 - 2033
6.4.3. Equipment
6.4.3.1. Equipment market, 2021 - 2033
6.4.3.2. Sperm Analyzer Systems Media
6.4.3.2.1. Sperm analyzer systems market, 2021 - 2033
6.4.3.3. Imaging Systems
6.4.3.3.1. Imaging systems market, 2021 - 2033
6.4.3.4. Ovum Aspiration Pumps
6.4.3.4.1. Ovum aspiration pumps market, 2021 - 2033
6.4.3.5. Micromanipulator Systems
6.4.3.5.1. Micromanipulator systems market, 2021 - 2033
6.4.3.6. Incubators
6.4.3.6.1. Incubators market, 2021 - 2033
6.4.3.7. Gas Analyzers
6.4.3.7.1. Gas analyzers market, 2021 - 2033
6.4.3.8. Laser Systems
6.4.3.8.1. Laser systems market, 2021 - 2033
6.4.3.9. Cryosystems
6.4.3.9.1. Cryosystems market, 2021 - 2033
6.4.3.10. Sperm Separation Devices
6.4.3.10.1. Sperm separation devices market, 2021 - 2033
6.4.3.11. IVF Cabinets
6.4.3.11.1. IVF cabinets market, 2021 - 2033
6.4.3.12. Anti-vibration Tables
6.4.3.12.1. Anti-vibration tables market, 2021 - 2033
6.4.3.13. Witness Systems
6.4.3.13.1. Witness systems market, 2021 - 2033
6.4.3.14. Others
6.4.3.14.1. Others market, 2021 - 2033
Chapter 7. Regional Outlook
7.1. IVF Market by Region: Key Marketplace Takeaway
7.2. North America
7.2.1. North America IVF market, 2021 - 2033
7.2.2. U.S.
7.2.2.1. U.S. estimated fertility rate, 2021 - 2033
7.2.2.2. Regulatory framework
7.2.2.3. Reimbursement scenario
7.2.2.4. Competitive scenario
7.2.2.5. U.S. IVF market, 2021 - 2033
7.2.3. Canada
7.2.3.1. Canada estimated fertility rate, 2021 - 2033
7.2.3.2. Regulatory framework
7.2.3.3. Reimbursement scenario
7.2.3.4. Competitive scenario
7.2.3.5. Canada IVF market, 2021 - 2033
7.3. Europe
7.3.1. Europe IVF market, 2021 - 2033
7.3.2. France
7.3.2.1. France estimated fertility rate, 2021 - 2033
7.3.2.2. Regulatory framework
7.3.2.3. Reimbursement scenario
7.3.2.4. Competitive scenario
7.3.2.5. France IVF market, 2021 - 2033
7.3.3. Germany
7.3.3.1. Germany estimated fertility rate, 2021 - 2033
7.3.3.2. Regulatory framework
7.3.3.3. Reimbursement Scenario
7.3.3.4. Competitive scenario
7.3.3.5. Germany IVF market, 2021 - 2033
7.3.4. Italy
7.3.4.1. Italy estimated fertility rate, 2021 - 2033
7.3.4.2. Regulatory framework
7.3.4.3. Reimbursement scenario
7.3.4.4. Competitive scenario
7.3.4.5. Italy IVF market, 2021 - 2033
7.3.5. Spain
7.3.5.1. Spain estimated fertility rate, 2021 - 2033
7.3.5.2. Regulatory framework
7.3.5.3. Reimbursement scenario
7.3.5.4. Competitive scenario
7.3.5.5. Spain IVF market, 2021 - 2033
7.3.6. UK
7.3.6.1. UK estimated fertility rate, 2021 - 2033
7.3.6.2. Regulatory framework
7.3.6.3. Reimbursement scenario
7.3.6.4. Competitive scenario
7.3.6.5. UK IVF market, 2021 - 2033
7.3.7. Belgium
7.3.7.1. Belgium estimated fertility rate, 2021 - 2033
7.3.7.2. Regulatory framework
7.3.7.3. Reimbursement scenario
7.3.7.4. Competitive scenario
7.3.7.5. Belgium IVF market, 2021 - 2033
7.3.8. Netherlands
7.3.8.1. Netherlands estimated fertility rate, 2021 - 2033
7.3.8.2. Regulatory framework
7.3.8.3. Reimbursement scenario
7.3.8.4. Competitive scenario
7.3.8.5. Netherlands IVF market, 2021 - 2033
7.3.9. Switzerland
7.3.9.1. Switzerland estimated fertility rate, 2021 - 2033
7.3.9.2. Regulatory framework
7.3.9.3. Reimbursement scenario
7.3.9.4. Competitive scenario
7.3.9.5. Switzerland IVF market, 2021 - 2033
7.3.10. Sweden
7.3.10.1. Sweden estimated fertility rate, 2021 - 2033
7.3.10.2. Regulatory framework
7.3.10.3. Reimbursement scenario
7.3.10.4. Competitive scenario
7.3.10.5. Sweden IVF market, 2021 - 2033
7.3.11. Denmark
7.3.11.1. Denmark estimated fertility rate, 2021 - 2033
7.3.11.2. Regulatory framework
7.3.11.3. Reimbursement scenario
7.3.11.4. Competitive scenario
7.3.11.5. Denmark IVF market, 2021 - 2033
7.3.12. Norway
7.3.12.1. Norway estimated fertility rate, 2021 - 2033
7.3.12.2. Regulatory framework
7.3.12.3. Reimbursement scenario
7.3.12.4. Competitive scenario
7.3.12.5. Norway IVF market, 2021 - 2033
7.4. Asia Pacific
7.4.1. Asia Pacific IVF market, 2021 - 2033
7.4.2. Japan
7.4.2.1. Japan estimated fertility rate, 2021 - 2033
7.4.2.2. Regulatory framework
7.4.2.3. Reimbursement scenario
7.4.2.4. Competitive scenario
7.4.2.5. Japan IVF market, 2021 - 2033
7.4.3. China
7.4.3.1. China estimated fertility rate, 2021 - 2033
7.4.3.2. Regulatory framework
7.4.3.3. Reimbursement scenario
7.4.3.4. Competitive scenario
7.4.3.5. China IVF market, 2021 - 2033
7.4.4. India
7.4.4.1. India estimated fertility rate, 2021 - 2033
7.4.4.2. Regulatory framework
7.4.4.3. Reimbursement scenario
7.4.4.4. Competitive scenario
7.4.4.5. India IVF market, 2021 - 2033
7.4.5. Australia
7.4.5.1. Australia estimated fertility rate, 2021 - 2033
7.4.5.2. Regulatory framework
7.4.5.3. Reimbursement scenario
7.4.5.4. Competitive scenario
7.4.5.5. Australia IVF market, 2021 - 2033
7.4.6. South Korea
7.4.6.1. South Korea estimated fertility rate, 2021 - 2033
7.4.6.2. Regulatory framework
7.4.6.3. Reimbursement scenario
7.4.6.4. Competitive scenario
7.4.6.5. South Korea IVF market, 2021 - 2033
7.4.7. Thailand
7.4.7.1. Thailand estimated fertility rate, 2021 - 2033
7.4.7.2. Regulatory framework
7.4.7.3. Reimbursement scenario
7.4.7.4. Competitive scenario
7.4.7.5. Thailand IVF market, 2021 - 2033
7.5. Latin America
7.5.1. Latin America IVF market, 2021 - 2033
7.5.2. Brazil
7.5.2.1. Brazil estimated fertility rate, 2021 - 2033
7.5.2.2. Regulatory framework
7.5.2.3. Reimbursement scenario
7.5.2.4. Competitive scenario
7.5.2.5. Brazil IVF market, 2021 - 2033
7.5.3. Mexico
7.5.3.1. Mexico estimated fertility rate, 2021 - 2033
7.5.3.2. Regulatory framework
7.5.3.3. Reimbursement scenario
7.5.3.4. Competitive scenario
7.5.3.5. Mexico IVF market, 2021 - 2033
7.5.4. Argentina
7.5.4.1. Argentina estimated fertility rate, 2021 - 2033
7.5.4.2. Regulatory framework
7.5.4.3. Reimbursement scenario
7.5.4.4. Competitive scenario
7.5.4.5. Argentina IVF market, 2021 - 2033
7.6. Middle East & Africa
7.6.1. MEA IVF market, 2021 - 2033
7.6.2. South Africa
7.6.2.1. South Africa estimated fertility rate, 2021 - 2033
7.6.2.2. Regulatory framework
7.6.2.3. Reimbursement scenario
7.6.2.4. Competitive scenario
7.6.2.5. South Africa IVF market, 2021 - 2033
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia estimated fertility rate, 2021 - 2033
7.6.3.2. Regulatory framework
7.6.3.3. Reimbursement scenario
7.6.3.4. Competitive scenario
7.6.3.5. Saudi Arabia IVF market, 2021 - 2033
7.6.4. UAE
7.6.4.1. UAE estimated fertility rate, 2021 - 2033
7.6.4.2. Regulatory framework
7.6.4.3. Reimbursement scenario
7.6.4.4. Competitive scenario
7.6.4.5. UAE IVF market, 2021 - 2033
Chapter 8. Competitive Analysis
8.1. Company Profiles
8.1.1. Suppliers
8.1.1.1. Vitrolife
8.1.1.1.1. Overview
8.1.1.1.2. Financial Performance
8.1.1.1.3. Product Benchmarking
8.1.1.1.4. Strategic Initiatives
8.1.1.2. Emd Serono, Inc.
8.1.1.2.1. Overview
8.1.1.2.2. Financial Performance
8.1.1.2.3. Product Benchmarking
8.1.1.2.4. Strategic Initiatives
8.1.1.3. FUJIFILM Irvine Scientific
8.1.1.3.1. Overview
8.1.1.3.2. Financial Performance
8.1.1.3.3. Product Benchmarking
8.1.1.3.4. Strategic Initiatives
8.1.1.4. The Cooper Companies, Inc.
8.1.1.4.1. Overview
8.1.1.4.2. Financial Performance
8.1.1.4.3. Product Benchmarking
8.1.1.4.4. Strategic Initiatives
8.1.1.5. Thermo Fisher Scientific, Inc.
8.1.1.5.1. Overview
8.1.1.5.2. Financial Performance
8.1.1.5.3. Product Benchmarking
8.1.1.5.4. Strategic Initiatives
8.1.1.6. Bayer AG
8.1.1.6.1. Overview
8.1.1.6.2. Financial Performance
8.1.1.6.3. Product Benchmarking
8.1.1.6.4. Strategic Initiatives
8.1.1.7. Merck & Co., Inc.
8.1.1.7.1. Overview
8.1.1.7.2. Financial Performance
8.1.1.7.3. Product Benchmarking
8.1.1.7.4. Strategic Initiatives
8.1.1.8. Cook Medical LLC (Cook Group)
8.1.1.8.1. Overview
8.1.1.8.2. Financial Performance
8.1.1.8.3. Product Benchmarking
8.1.1.8.4. Strategic Initiatives
8.1.1.9. Genea Biomedx
8.1.1.9.1. Overview
8.1.1.9.2. Financial Performance
8.1.1.9.3. Product Benchmarking
8.1.1.9.4. Strategic Initiatives
8.1.1.10. Ferring Pharmaceutical B.V.
8.1.1.10.1. Overview
8.1.1.10.2. Financial Performance
8.1.1.10.3. Product Benchmarking
8.1.1.10.4. Strategic Initiatives
8.1.2. Service Providers
8.1.2.1. Nova IVF
8.1.2.1.1. Overview
8.1.2.1.2. Financial Performance
8.1.2.1.3. Service Benchmarking
8.1.2.1.4. Strategic Initiatives
8.1.2.2. Boston IVF
8.1.2.2.1. Overview
8.1.2.2.2. Financial Performance
8.1.2.2.3. Service Benchmarking
8.1.2.2.4. Strategic Initiatives
8.1.2.3. RMA Network (Reproductive Medicine Associates)
8.1.2.3.1. Overview
8.1.2.3.2. Financial Performance
8.1.2.3.3. Service Benchmarking
8.1.2.3.4. Strategic Initiatives
8.1.2.4. TFP Thames Valley Fertility
8.1.2.4.1. Overview
8.1.2.4.2. Financial Performance
8.1.2.4.3. Service Benchmarking
8.1.2.4.4. Strategic Initiatives
8.1.2.5. Fortis Healthcare
8.1.2.5.1. Overview
8.1.2.5.2. Financial Performance
8.1.2.5.3. Service Benchmarking
8.1.2.5.4. Strategic Initiatives
8.1.2.6. U.S. Fertility
8.1.2.6.1. Overview
8.1.2.6.2. Financial Performance
8.1.2.6.3. Service Benchmarking
8.1.2.6.4. Strategic Initiatives
8.2. Company Categorization
8.3. Company Market Position Analysis
8.4. Strategy Mapping
Chapter 9. Recommendations/Key Market Insights
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers